Compare BIPC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIPC | BLTE |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | United States |
| Employees | 250000 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 6.6B |
| IPO Year | 2019 | 2021 |
| Metric | BIPC | BLTE |
|---|---|---|
| Price | $37.38 | $154.78 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $45.00 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 989.1K | 112.2K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.85 | N/A |
| Revenue Next Year | $5.94 | $492.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.18 | $56.68 |
| 52 Week High | $51.72 | $200.00 |
| Indicator | BIPC | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 35.85 | 41.83 |
| Support Level | N/A | $148.06 |
| Resistance Level | $40.93 | $161.28 |
| Average True Range (ATR) | 1.37 | 6.15 |
| MACD | -0.34 | -1.15 |
| Stochastic Oscillator | 37.42 | 8.53 |
Brookfield Infrastructure Corp is an indirect subsidiary of the partnership of the diversified infrastructure owner and operators. Its business is comprised of a U.K. regulated distribution operation, a Brazilian regulated natural gas transmission operation and an international intermodal logistics operation. Geographically, the company generates a majority of its revenue from Brazil and rest from United Kingdom, United States, France, Switzerland, Singapore, China, Denmark, Hong Kong, Germany and Others.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.